All In Biotech

Drug Trial Radar · NCT06026501

A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

A Phase Ib/II Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Last checked: Nov 19, 2026Latest source record: Sep 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 31, 2023

Primary completion

Aug 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
Collaborators
Shanghai HyaMab Biotech Co.,Ltd.
First posted
Sep 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a one-arm, open, multicenter phase 1b/2 clinical trial of PE0116combined with PE0105 in patients with Advanced Solid Tumors, aiming at exploring the MTD and RP2D and observing the preliminary efficacy.The trial can be divided into two parts: dose escalation part and expansion part.PE0105 is administered as a fixed-dose intravenous injection(3mg/kg Q3w).

Conditions

  • Advanced Solid Tumors

Interventions

  • PE0116,PE0105Drug

    1. PE0116: 4-1BB Agonist Antibody Drug 2. PE0105: PD-1 Monoclonal Antibody Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limited toxicities evaluated by NCI-CTCAE v5.0Time frame: From time of first dose to 21 days after the first dose.
  2. Adverse events evaluated by NCI CTCAE v5.0Time frame: From time of first dose to 90 days after the last dose.
  3. Recommended Phase 2 DoseTime frame: From time of first dose of the first patient to the last dose of the last patient in phase 1b..
  4. Objective response rateTime frame: From the first dose to the date of disease progression or date of death from any cause, whichever comes first,up to 24months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.